Trillium Therapeutics Inc.
SEC CIK 1616212 · TRIL · last insider filing 2021-11-19
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Beshar Luke M | Director | filed 2021 - 2021 |
| Myers Scott Dunseth | Director | filed 2021 - 2021 |
| Pucci Paolo | Director | filed 2021 - 2021 |
| Kamarck Michael E. | Director | filed 2021 - 2021 |
| Walker Paul Edward | Director | filed 2021 - 2021 |
| Mackey Catherine J | Director | filed 2021 - 2021 |
| Tayton-Martin Helena Katrina | Director | filed 2021 - 2021 |
| Skvarka Jan | Director · President and CEO | filed 2021 - 2021 |
| Kirkman Robert L | Director | filed 2021 - 2021 |
| Reynolds Thomas C | Director | filed 2021 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Parsons James T. | Chief Financial Officer | filed 2021 - 2021 |
| Bruns Ingmar | Chief Medical Officer | filed 2021 - 2021 |
| Petrova Penka | Chief Development Officer | filed 2021 - 2021 |
| Harrison Rosemary | See Remarks | filed 2021 - 2021 |
| Uger Robert | Chief Scientific Officer | filed 2021 - 2021 |
| Looker Benjamin | General Counsel | filed 2021 - 2021 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.